Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

462
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
462
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

891
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
891
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

248
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
248

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A PSC-tailored deep learning model for liver segmentation on fat-saturated T2-weighted MR: Robustness to hepatic dysmorphia and multicentre generalisability.

European journal of radiology·2026
Same author

Does Casting Material Influence the Number of Casts Required Before Achilles Tenotomy in the Ponseti Treatment of Severe Idiopathic Clubfoot?

Journal of clinical medicine·2026
Same author

Definition, diagnosis, and treatment of primary biliary cholangitis - autoimmune hepatitis (PBC-AIH) variant: An international expert delphi consensus.

Hepatology (Baltimore, Md.)·2026
Same author

Beyond the Graft: Optimizing Post-Transplant Care in Primary Sclerosing Cholangitis.

Journal of clinical medicine·2026
Same author

Quantitative magnetic resonance cholangiopancreatography metrics improve prognostication in primary sclerosing cholangitis.

JHEP reports : innovation in hepatology·2026
Same author

The ethics of unlicensed therapy use in primary biliary cholangitis: a counter view.

Nature reviews. Gastroenterology & hepatology·2026

Related Experiment Video

Updated: Mar 19, 2026

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis
04:38

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis

Published on: March 28, 2018

16.7K

Toward precision medicine in primary biliary cholangitis.

Marco Carbone1, Vincenzo Ronca2, Savino Bruno2

  • 1Academic Department of Medical Genetics, University of Cambridge, Cambridge, United Kingdom; MRC Epidemiology Unit, University of Cambridge, Cambridge, United Kingdom; Liver Unit, Humanitas Clinical and Research Institute, Rozzano (Milan), Italy.

Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
|June 22, 2016
PubMed
Summary

Precision medicine offers a tailored approach to managing primary biliary cholangitis (PBC), a chronic liver disease. This strategy moves beyond the current one-size-fits-all treatment for PBC, leveraging new research and therapies.

Keywords:
Precision medicinePrimary biliary cholangitisRisk-stratification

Related Experiment Videos

Last Updated: Mar 19, 2026

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis
04:38

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis

Published on: March 28, 2018

16.7K

Area of Science:

  • Hepatology and Translational Epidemiology
  • Chronic cholestatic liver disease research

Background:

  • Primary biliary cholangitis (PBC) presents heterogeneously in patients regarding symptoms and disease progression.
  • Current clinical management of PBC employs a uniform, 'one size fits all' therapeutic strategy.
  • The emergence of -omics and large patient cohorts presents an opportunity for translational epidemiology in PBC.

Purpose of the Study:

  • To introduce the concept of precision medicine for primary biliary cholangitis.
  • To review existing risk-stratification methods in PBC.
  • To explore the future development of precision medicine in PBC.

Main Methods:

  • Review of current literature on precision medicine.
  • Analysis of existing risk-stratification approaches in PBC.
  • Discussion of emerging therapeutic agents for PBC.

Main Results:

  • The heterogeneity of PBC necessitates a move from standardized treatment.
  • Advancements in -omics and data analysis enable personalized risk assessment.
  • Novel therapies are under development, aligning with precision medicine principles.

Conclusions:

  • Precision medicine holds significant promise for optimizing primary biliary cholangitis treatment.
  • Personalized risk-stratification and targeted therapies can improve patient outcomes in PBC.
  • The integration of translational epidemiology and novel agents will shape the future of PBC care.